148 related articles for article (PubMed ID: 35184152)
1. Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing.
Ebbelaar CF; Schrader AMR; van Dijk M; Meijers RWJ; de Leng WWJ; Bloem LT; Jansen AML; Blokx WAM;
Mod Pathol; 2022 Aug; 35(8):1110-1120. PubMed ID: 35184152
[TBL] [Abstract][Full Text] [Related]
2. β-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors.
de la Fouchardière A; Caillot C; Jacquemus J; Durieux E; Houlier A; Haddad V; Pissaloux D
Virchows Arch; 2019 May; 474(5):539-550. PubMed ID: 30756182
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of atypical deep penetrating nevus progressing to melanoma.
Isales MC; Khan AU; Zhang B; Compres EV; Kim D; Tan TL; Beaubier N; Gerami P
J Cutan Pathol; 2020 Dec; 47(12):1150-1154. PubMed ID: 32526042
[TBL] [Abstract][Full Text] [Related]
4. Combined WNT-activated deep-penetrating/plexiform melanocytoma: insights into clinicopathological and molecular characterization.
Castillo P; Castrejon N; Marginet M; Massi D; Alamon F; Teixido C; Montironi C; Garcia-Herrera A; Albero-Gonzalez R; Matas J; Puig S; Alos L
Clin Exp Dermatol; 2024 Mar; 49(4):356-363. PubMed ID: 37995304
[TBL] [Abstract][Full Text] [Related]
5. Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
Magro CM; Abraham RM; Guo R; Li S; Wang X; Proper S; Crowson AN; Mihm M
Eur J Dermatol; 2014; 24(5):594-602. PubMed ID: 25118781
[TBL] [Abstract][Full Text] [Related]
6. PRAME and LEF1 in Combined Deep Penetrating Nevus and Combined Blue Nevus: Utility and Pitfalls.
Vanderbeck K; Rothrock AT; Cho WC; Nagarajan P; Aung PP; Hudgens C; Bassett RL; Ivan D; Prieto VG; Curry JL; Torres-Cabala CA
Am J Dermatopathol; 2023 Aug; 45(8):549-556. PubMed ID: 37462205
[TBL] [Abstract][Full Text] [Related]
7. An Atypical Deep Penetrating Nevus With Mutations in Beta Catenin , BRAFV600E , and IDH1R132C in an 8-Year-Old Boy.
Ireland AM; Wood BA; Whitfield J; Amanuel B; Harvey NT; Mesbah Ardakani N
Am J Dermatopathol; 2022 Aug; 44(8):607-610. PubMed ID: 35385855
[TBL] [Abstract][Full Text] [Related]
8. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
[TBL] [Abstract][Full Text] [Related]
9. Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
Urso C
Am J Dermatopathol; 2019 Sep; 41(9):623-629. PubMed ID: 31433323
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Utility of LEF1 Immunohistochemistry in Differentiating Deep Penetrating Nevi From Histologic Mimics.
Raghavan SS; Saleem A; Wang JY; Rieger KE; Brown RA; Novoa RA
Am J Surg Pathol; 2020 Oct; 44(10):1413-1418. PubMed ID: 32520758
[TBL] [Abstract][Full Text] [Related]
12. Melanocytic naevi, melanocytomas and emerging concepts.
Yeh I
Pathology; 2023 Mar; 55(2):178-186. PubMed ID: 36642570
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing revealing TP53 mutation as potential genetic driver in dermal deep-seated melanoma arising in giant congenital nevus in adult patients: A unique case report and review of the literature.
Ricci C; Ambrosi F; Grillini M; Serra M; Melotti B; Gruppioni E; Altimari A; Fiorentino M; Dika E; Lambertini M; Corti B
J Cutan Pathol; 2020 Dec; 47(12):1164-1169. PubMed ID: 32643812
[TBL] [Abstract][Full Text] [Related]
14. Melanocytic lesions, Spitz tumors, and Don Ferrante's logic.
Urso C
Am J Dermatopathol; 2007 Oct; 29(5):491-4. PubMed ID: 17890925
[No Abstract] [Full Text] [Related]
15. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
[TBL] [Abstract][Full Text] [Related]
16. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
17. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
[TBL] [Abstract][Full Text] [Related]
18. 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms.
Lee JJ; Vilain RE; Granter SR; Hu NR; Bresler SC; Xu S; Frank AH; Mihm MC; Saw RP; Fletcher CD; Scolyer RA; Murphy GF; Lian CG
J Cutan Pathol; 2017 Mar; 44(3):249-255. PubMed ID: 28032662
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.
See SHC; Finkelman BS; Yeldandi AV
Pathol Res Pract; 2020 Sep; 216(9):153105. PubMed ID: 32825968
[TBL] [Abstract][Full Text] [Related]
20. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]